Cevolisiran
RNA / oligonucleotide
Also known as ALXN2030
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Complement C3 drugs
Pegcetacoplan, Pegcetacoplan ophthalmic, ARO-C3. Compare all 4 Complement C3 drugs
3 other tracked programmes target this mechanism, 2 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cevolisiran: this drug | Phase 2 | RNA / oligonucleotide | Complement C3 | not yet graded | No reviewed efficacy summary | |
| Pegcetacoplan (Empaveli) | Approved(overall) | Peptide | Complement C3 | Partial signal | NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666) | |
| Pegcetacoplan Ophthalmic (Syfovre) | Approved(overall) | Peptide | Complement C3, Complement C3 / C3b | Reliable signal | NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218) NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed | |
| ARO-C3 | Phase 1/2(overall) | RNA / oligonucleotide | Complement C3 | not yet graded | No reviewed efficacy summary |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cevolisiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.